The Claim
In adults with type 2 diabetes and chronic kidney disease who are already receiving ACE inhibitor or ARB therapy, weekly subcutaneous administration of semaglutide at a dose of 1.0 mg slows the annual decline in estimated glomerular filtration rate (eGFR) by 1.16 mL/min/1.73m² compared to placebo, suggesting a protective effect on kidney function over time.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
For people with type 2 diabetes and kidney problems, taking a weekly semaglutide shot might help slow down how fast their kidneys get worse.
See the scientific wording
In adults with type 2 diabetes and chronic kidney disease on ACE inhibitor or ARB therapy, weekly subcutaneous semaglutide at 1.0 mg slows the annual decline in eGFR by 1.16 mL/min/1.73m² compared to placebo, indicating a protective effect on kidney function over time.
What the research says
1 studyStudy: Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.
The study tested the same diabetes medicine (semaglutide) and found it slowed kidney function decline by exactly the amount claimed, so the evidence supports the claim.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.